Sinopharm Group Co. Ltd.

SEHK:1099 Stock Report

Market Cap: HK$62.6b

Sinopharm Group Balance Sheet Health

Financial Health criteria checks 6/6

Sinopharm Group has a total shareholder equity of CN¥120.3B and total debt of CN¥68.6B, which brings its debt-to-equity ratio to 57%. Its total assets and total liabilities are CN¥383.4B and CN¥263.1B respectively. Sinopharm Group's EBIT is CN¥22.3B making its interest coverage ratio 10.3. It has cash and short-term investments of CN¥63.8B.

Key information

57.0%

Debt to equity ratio

CN¥68.56b

Debt

Interest coverage ratio10.3x
CashCN¥63.81b
EquityCN¥120.32b
Total liabilitiesCN¥263.08b
Total assetsCN¥383.39b

Recent financial health updates

Recent updates

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Mar 06
Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Jan 31
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Dec 31
There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

Nov 29
Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Nov 14
If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Nov 01
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sep 20
Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sep 05
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Aug 18
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Aug 02
Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Jun 01
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Apr 26
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Feb 27
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Jan 19
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Is Sinopharm Group (HKG:1099) A Risky Investment?

Nov 18
Is Sinopharm Group (HKG:1099) A Risky Investment?

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Oct 03
Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jul 31
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Jul 10
Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Jun 05
Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Apr 11
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Mar 21
A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Mar 03
Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jan 09
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Dec 19
Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Dec 01
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Sep 10
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Aug 28
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Jun 13
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Jun 06
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

May 24
Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

May 11
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

Mar 20
Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Mar 05
We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend

Feb 18
You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend

Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?

Feb 03
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?

Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?

Jan 19
Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?

At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?

Jan 06
At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?

What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?

Dec 25
What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?

Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares

Dec 15
Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Dec 04
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years

Nov 25
Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years

Financial Position Analysis

Short Term Liabilities: 1099's short term assets (CN¥336.8B) exceed its short term liabilities (CN¥241.5B).

Long Term Liabilities: 1099's short term assets (CN¥336.8B) exceed its long term liabilities (CN¥21.6B).


Debt to Equity History and Analysis

Debt Level: 1099's net debt to equity ratio (4%) is considered satisfactory.

Reducing Debt: 1099's debt to equity ratio has reduced from 80.6% to 57% over the past 5 years.

Debt Coverage: 1099's debt is well covered by operating cash flow (25%).

Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (10.3x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.